Opthea (ASX:OPT) reported Monday fiscal first-half earnings of AU$0.2552 per share, compared to a loss of AU$0.1650 a year earlier.

Revenue for the six months ended Dec. 31, 2025, was AU$1,000, compared with AU$240,000 a year earlier.

The company said it expects to rename itself to reflect its focus on Lymphangioleiomyomatosis, a rare disease that predominantly affects women.